HER2 testing in gastric cancer

A practical approach

Josef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y. Osamura, Frédérique Penault-Llorca, Marc Van De Vijver, Giuseppe Viale

Research output: Contribution to journalArticle

292 Citations (Scopus)

Abstract

Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2+)-positive (immunohistochemistry 3+ or immunohistochemistry 2/fluorescence in situ hybridization-positive or immunohistochemistry 2/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2+ testing and scoring to ensure accurate identification of patients eligible for treatment. HER2+ testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2+ heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2+ testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2+ protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2+ testing in gastric cancer, irrespective of the experience of HER2+ testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2+ testing and scoring in patients with gastric and gastro-esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2+ testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2+ testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.

Original languageEnglish
Pages (from-to)637-650
Number of pages14
JournalModern Pathology
Volume25
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Stomach Neoplasms
Immunohistochemistry
Staining and Labeling
Breast Neoplasms
Fluorescence In Situ Hybridization
Silver
In Situ Hybridization
Stomach
Esophageal Neoplasms
Fluorouracil
Patient Selection
Cisplatin
Japan
Adenocarcinoma
Therapeutics
Membranes
Trastuzumab
Neoplasms
Proteins

Keywords

  • gastric cancer
  • guidance
  • HER2 testing
  • immunohistochemistry
  • in situ hybridization
  • quality assurance
  • trastuzumab

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Rüschoff, J., Hanna, W., Bilous, M., Hofmann, M., Osamura, R. Y., Penault-Llorca, F., ... Viale, G. (2012). HER2 testing in gastric cancer: A practical approach. Modern Pathology, 25(5), 637-650. https://doi.org/10.1038/modpathol.2011.198

HER2 testing in gastric cancer : A practical approach. / Rüschoff, Josef; Hanna, Wedad; Bilous, Michael; Hofmann, Manfred; Osamura, Robert Y.; Penault-Llorca, Frédérique; Van De Vijver, Marc; Viale, Giuseppe.

In: Modern Pathology, Vol. 25, No. 5, 05.2012, p. 637-650.

Research output: Contribution to journalArticle

Rüschoff, J, Hanna, W, Bilous, M, Hofmann, M, Osamura, RY, Penault-Llorca, F, Van De Vijver, M & Viale, G 2012, 'HER2 testing in gastric cancer: A practical approach', Modern Pathology, vol. 25, no. 5, pp. 637-650. https://doi.org/10.1038/modpathol.2011.198
Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F et al. HER2 testing in gastric cancer: A practical approach. Modern Pathology. 2012 May;25(5):637-650. https://doi.org/10.1038/modpathol.2011.198
Rüschoff, Josef ; Hanna, Wedad ; Bilous, Michael ; Hofmann, Manfred ; Osamura, Robert Y. ; Penault-Llorca, Frédérique ; Van De Vijver, Marc ; Viale, Giuseppe. / HER2 testing in gastric cancer : A practical approach. In: Modern Pathology. 2012 ; Vol. 25, No. 5. pp. 637-650.
@article{6e09f5b859f5423db78aff77c1c2f8b3,
title = "HER2 testing in gastric cancer: A practical approach",
abstract = "Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2+)-positive (immunohistochemistry 3+ or immunohistochemistry 2/fluorescence in situ hybridization-positive or immunohistochemistry 2/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2+ testing and scoring to ensure accurate identification of patients eligible for treatment. HER2+ testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2+ heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2+ testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2+ protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2+ testing in gastric cancer, irrespective of the experience of HER2+ testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2+ testing and scoring in patients with gastric and gastro-esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2+ testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2+ testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.",
keywords = "gastric cancer, guidance, HER2 testing, immunohistochemistry, in situ hybridization, quality assurance, trastuzumab",
author = "Josef R{\"u}schoff and Wedad Hanna and Michael Bilous and Manfred Hofmann and Osamura, {Robert Y.} and Fr{\'e}d{\'e}rique Penault-Llorca and {Van De Vijver}, Marc and Giuseppe Viale",
year = "2012",
month = "5",
doi = "10.1038/modpathol.2011.198",
language = "English",
volume = "25",
pages = "637--650",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - HER2 testing in gastric cancer

T2 - A practical approach

AU - Rüschoff, Josef

AU - Hanna, Wedad

AU - Bilous, Michael

AU - Hofmann, Manfred

AU - Osamura, Robert Y.

AU - Penault-Llorca, Frédérique

AU - Van De Vijver, Marc

AU - Viale, Giuseppe

PY - 2012/5

Y1 - 2012/5

N2 - Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2+)-positive (immunohistochemistry 3+ or immunohistochemistry 2/fluorescence in situ hybridization-positive or immunohistochemistry 2/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2+ testing and scoring to ensure accurate identification of patients eligible for treatment. HER2+ testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2+ heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2+ testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2+ protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2+ testing in gastric cancer, irrespective of the experience of HER2+ testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2+ testing and scoring in patients with gastric and gastro-esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2+ testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2+ testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.

AB - Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is approved by the European Medicines Agency for the treatment of patients with human epidermal growth factor receptor 2 (HER2+)-positive (immunohistochemistry 3+ or immunohistochemistry 2/fluorescence in situ hybridization-positive or immunohistochemistry 2/silver in situ hybridization-positive) metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Approvals are underway in other countries, with recent approvals granted in the United States and Japan. Experience and data from trastuzumab use in breast cancer have highlighted the importance of quality HER2+ testing and scoring to ensure accurate identification of patients eligible for treatment. HER2+ testing in gastric cancer differs from testing in breast cancer due to inherent differences in tumor biology; gastric cancer more frequently shows HER2+ heterogeneity (focal staining) and incomplete membrane staining. Consequently, gastric cancer-specific HER2+ testing protocols have been developed and standardized and it is imperative that these recommendations be adhered to. Given the predictive value of HER2+ protein levels with response in the trastuzumab for GAstric cancer study (ToGA), immunohistochemistry should be the initial testing methodology and fluorescence in situ hybridization or silver in situ hybridization should be used to retest immunohistochemistry 2+ samples. Wherever possible, bright-field methodologies should be used as these are considered to be superior to fluorescent methodologies at identifying heterogeneous staining. Specific training is required before embarking on HER2+ testing in gastric cancer, irrespective of the experience of HER2+ testing in breast cancer. This paper provides the most up-to-date practical guidance on HER2+ testing and scoring in patients with gastric and gastro-esophageal junction cancer, as agreed by a panel of expert pathologists with extensive experience of HER2+ testing particularly reflecting the European Medicines Agency-approved indication. It is anticipated that these recommendations should ensure accurate and consistent HER2+ testing, which will allow appropriate selection of patients eligible for treatment with trastuzumab.

KW - gastric cancer

KW - guidance

KW - HER2 testing

KW - immunohistochemistry

KW - in situ hybridization

KW - quality assurance

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84860487790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860487790&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.198

DO - 10.1038/modpathol.2011.198

M3 - Article

VL - 25

SP - 637

EP - 650

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -